[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593497":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":36,"locations":46,"responsibleParty":85,"collaborators":23,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":23,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":49,"whyStopped":23,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental arm","EXPERIMENTAL","TEP exam, MRI exam, oculometry assessment and cognitive tasks",[13,14,15,16],"Drug: a positon emission tomography (PET) exam","Other: MRI Contrast","Other: oculometry assessment","Other: cognitive exams",[18,24,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","a positon emission tomography (PET) exam","TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)",[9],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"MRI Contrast","Data acquisition will include different sequences (anatomical MRI, resting fMRI). The MRI sequences performed will be anatomical imaging (i.e. T1 imaging, FLAIR), a diffusion sequence, a neuromelanin-sensitive sequence and functional imaging at rest (i.e. \"the resting state\", which allows the functional connectivity within the so-called \"default\" network to be assessed).",[9],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":23},"oculometry assessment","Pupillometry and oculometry will be conducted using an EyeBrain medical device (class IIa). Several cognitive tasks will be submitted to the participant, during which the same measurements will be taken. Different stimuli will be presented on the computer screen (visual scenes, text, geometric shapes) during the eye tracking measurement, and an instruction (cognitive task, such as semantic categorization, free exploration of the gaze, reading, saccade execution) will be associated with each type of stimulus. The successive stimuli will be spaced more than 7 secondes apart in order to allow the pupillary response to the first stimulus to be recorded and then to return to the basal diameter before presentation of the next stimulus.",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"cognitive exams","Cognitive measures will be acquired during an evaluation session through 6 interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare.",[9],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":23,"email":41},"PAYOUX P Pierre, MD","CONTACT","+33 (0)562746169","payoux.p@chu-toulouse.fr",{"name":43,"role":39,"phone":44,"phoneExt":23,"email":45},"DELRIEU J Julien, MD","+33 (0)5 61 77 70 58","dlerieu.j@chu-toulouse.fr",[47],{"facility":48,"status":49,"city":50,"state":23,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University Hospital of Toulouse","RECRUITING","Toulouse","31059","France","FR",{"type":55,"coordinates":56},"Point",[57,58],1.44367,43.60426,{"lat":58,"lon":57},[61,64,67,69,70,73,75,77,79,81,83],{"name":62,"role":39,"phone":63,"phoneExt":23,"email":41},"Payoux Pierre, MD","+33 (0)5 62 74 61 69",{"name":65,"role":39,"phone":44,"phoneExt":23,"email":66},"Delrieu Julien, MD","delrieu.j@chu-toulouse.fr",{"name":62,"role":68,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"name":65,"role":68,"phone":23,"phoneExt":23,"email":23},{"name":71,"role":72,"phone":23,"phoneExt":23,"email":23},"GIROUD Marine","SUB_INVESTIGATOR",{"name":74,"role":72,"phone":23,"phoneExt":23,"email":23},"SASTRE Nathalie",{"name":76,"role":72,"phone":23,"phoneExt":23,"email":23},"HITZEL Anne",{"name":78,"role":72,"phone":23,"phoneExt":23,"email":23},"ANGIONI Davide",{"name":80,"role":72,"phone":23,"phoneExt":23,"email":23},"ABELLAN VAN KAN Gabor",{"name":82,"role":72,"phone":23,"phoneExt":23,"email":23},"OUSSET Jean-Pierre",{"name":84,"role":72,"phone":23,"phoneExt":23,"email":23},"FAISANT Catherine",{"type":86,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100593497","phase-2-biomarkers-of-the-locus-coeruleus-nucleus-links-with-early-tau-pathology-cognition-and-alzheimers-disease-risk-100593497",false,"NCT07007208","Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk","Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk.","Locus-Tau","Inclusion Criteria:\n\n* Participant in the INSPIRE-T cohort\n* Normal cognitive assessment\n* MMSE score ≥ 27 out of 30 (Mini-Mental State Examination)\n* Normal visual abilities (in corrected or uncorrected vision)\n* Normal motor skills\n\nExclusion Criteria:\n\n* Subjects with a contraindication to MRI exam\n* Subjects with a known allergic reaction to the PET radiopharmaceutical (\\[18F\\] Flortaucipir) or any of its excipients\n* Subjects with an ophthalmological pathology making oculometric measurements difficult\n* Subjects with a neurodegenerative condition or a history of cerebral ischemia\n* Subjects with a psychiatric disorder and a PHQ-9 score \\> 10 or under treatment with NRI",true,"ALL","60 Years","100 Years",{"count":100,"type":101},100,"ESTIMATED","INTERVENTIONAL",[104],"PHASE2","Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.",[107],"Alzheimer Disease",[109,110,111,112,113],"PET","MRI","occulometry","locus coeruleus","Alzheimer disease","2026-07-15",{"date":116,"type":117},"2026-07-17","ACTUAL",{"date":119,"type":117},"2026-02-02",{"date":121,"type":101},"2029-01-31",{"name":5,"class":6},1]